Istituti Clinici Scientifici Maugeri SpA

icsmaugeri.it

Total trials

112

Active

49

Phase 3

0

Total enrollment

18,605

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Pembrolizumab2
Cisplatin1
Docetaxel1
Carboplatin1
Prismatic adaptation and electric stimulation1

Next readouts

  • 2026-07-15
  • 2026-11
  • 2026-12

Top conditions

  • Breast Cancer12
  • COPD6
  • Asthma5
  • Parkinson Disease5
  • Stroke5
  • Healthy Volunteers4
  • Multiple Sclerosis3
  • Rehabilitation3

Frequently asked questions about Istituti Clinici Scientifici Maugeri SpA

How many clinical trials does Istituti Clinici Scientifici Maugeri SpA have on ClinicalTrials.gov?
Istituti Clinici Scientifici Maugeri SpA is listed as the lead sponsor on 112 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
How many of Istituti Clinici Scientifici Maugeri SpA's trials are in Phase 3?
0 of Istituti Clinici Scientifici Maugeri SpA's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Istituti Clinici Scientifici Maugeri SpA focus on?
Istituti Clinici Scientifici Maugeri SpA's most-studied conditions on ClinicalTrials.gov are Breast Cancer, COPD, Asthma, Parkinson Disease, Stroke.
When are Istituti Clinici Scientifici Maugeri SpA's next clinical trial readouts?
Istituti Clinici Scientifici Maugeri SpA has 3 upcoming primary-completion readouts tracked here; the soonest is “Prismatic Lenses and tDCS in Neglect”, expected around 2026-07-15.